Renal Cell Carcinoma

The FDA has cleared HuidaGene Therapeutics' investigational new drug application for HG202, the first CRISPR-Cas13 RNA-editing therapy to enter...

Clinical Trial Update: Recent News From Editas...

May. 3, 2023

In this clinical update, we look at recent advances in two clinical-stage gene-editing programmes. Editas Medicine's sickle cell disease candidate...

Clinical Trial Roundup: Gene-Editing Therapies for...

Mar. 1, 2023

In this update, we summarise the two ongoing gene-editing clinical trials for renal cell carcinoma, which is the most common form of kidney cancer...

Clinical Roundup: Gene-Edited CAR T Therapies

Feb. 6, 2023

In recent years, researchers have turned to gene editing to address the limitations of CAR T therapies. This roundup summarises the clinical-stage...

Clinical update: FDA Upgrades Status for Two...

Mar. 16, 2022

This week's update includes news about two gene-edited therapies for cancer. Allogene Therapeutics' ALLO-316 has been granted Fast Track Designation...

Gene-Editing IND and Pre-clinical Update

Dec. 23, 2020

Update on Allogene Therapeutics off-the-shelf CAR-T cancer therapies. This week’s gene-editing update looks at an investigational new drug (IND)...

Renal Cell Carcinoma

Renal Cell Carcinoma, RCC, (NCT06245915)
Sponsors:
Arsenal Biosciences, Inc.

IND Enabling

Phase I

Phase II

Phase III

Renal Cell Carcinoma, RCC, (NCT02867332)
Sponsors:
Peking University

IND Enabling

Phase I

Phase II

Phase III

Renal Cell Carcinoma, RCC, (NCT04696731)
Sponsors:
Allogene Therapeutics, Inc.

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Renal Cell Carcinoma, RCC, (NCT04438083)
Sponsors:
CRISPR Therapeutics AG

IND Enabling

Phase I

Phase II

Phase III